Abstract
Gemcitabine is a cytotoxic nucleoside analog, which is widely used in the treatment of malignancies. Interindividual differences in gemcitabine pharmacokinetics and pharmacodynamics have been demonstrated. Pharmacogenetic factors may account for a significant proportion of these differences. This review provides an update on the pharmacogenetics of gemcitabine and its influence on gemcitabine efficacy and toxicity.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antimetabolites, Antineoplastic* / pharmacokinetics
-
Antimetabolites, Antineoplastic* / pharmacology
-
Antimetabolites, Antineoplastic* / toxicity
-
Cytidine Deaminase / genetics
-
Cytidine Deaminase / metabolism
-
Deoxycytidine / analogs & derivatives*
-
Deoxycytidine / pharmacokinetics
-
Deoxycytidine / pharmacology
-
Deoxycytidine / toxicity
-
Deoxycytidine Kinase / genetics
-
Deoxycytidine Kinase / metabolism
-
Ethnicity / genetics
-
Gemcitabine
-
Humans
-
Nucleoside Transport Proteins / genetics
-
Nucleoside Transport Proteins / metabolism
-
Nucleotidases / genetics
-
Nucleotidases / metabolism
-
Pharmacogenetics*
-
Polymorphism, Genetic
-
Ribonucleotide Reductases / genetics
-
Ribonucleotide Reductases / metabolism
Substances
-
Antimetabolites, Antineoplastic
-
Nucleoside Transport Proteins
-
Deoxycytidine
-
Ribonucleotide Reductases
-
Deoxycytidine Kinase
-
Nucleotidases
-
Cytidine Deaminase
-
Gemcitabine